Pipeline

The Company’s biological targets are centered around PI3K/Akt/mTOR pathway in signal transduction involving cancer cells. This pathway is frequently activated in several types of cancers. Compounds directed toward these mechanisms are kinase inhibitors. Because these compounds are not of the typical “cytotoxic” class of chemotherapy, they are better tolerated by cancer patients, which can lead to a higher quality of life while undergoing treatments. Programs in the Company’s pipeline are presented below.

• mTOR pathway inhibitors - EM100 Series: 
  EM101 is a development candidate unrelated to rapamycin with a low MW (~300) and has additional kinase and cell cycle inhibitory activity. Proof-of efficacy has been shown in a PC-3 xenograft model of human prostate cancer.
  

• Akt pathway inhibitors - EM300 Series: 
  EM370 is a series showing direct Akt binding as well as inhibitory activity against kinases that activate Akt
  

• Angiogenesis inhibitors - EM400 Series: 
  EM400 is a series in lead-optimization with a unique multi-kinase inhibitor profile confirmed by biochemical screening

The compounds described above inhibit clinically proven molecular targets for cancer treatment and highlight the pathways and targets being pursued by Emiliem.  Each pipeline entry represents a multiple target approach with a single agent that can serve as mono-therapy or can enhance other therapies including cytotoxics when used in combination. The pipeline is focused on cell-survival, cell-cycle and angiogenesis pathways in multiple cancers.  Work is on-going to determine relevant molecular signatures that can be used for selecting specific cancers and patients for clinical trials.